biogen

Health Alzheimer’s drug approval by FDA ‘rife with irregularities,’ Congress finds after 18-month investigation
BYThe Associated Press
December 30, 2022
Health Congressional investigators say the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm was ‘rife with irregularities’
BYFiona Rutherford, Celine Castronuovo, and others
December 30, 2022
Health Breakthrough Alzheimer’s trial results show experimental drug significantly slows the disease
BYMichelle Fay Cortez and Bloomberg
September 28, 2022
Health Inside the lobbying push to get Medicare to pay for a controversial Alzheimer’s drug
BYArthur Allen and Kaiser Health News
February 16, 2022
Health Medicare ordered to reassess premium hike for Alzheimer’s drug
BYRicardo Alonso-Zaldivar and The Associated Press
January 10, 2022
Health Biogen slashes cost of Alzheimer’s drug by 50% six months after FDA approval
BYTimothy Annett and Bloomberg
December 20, 2021

Newsletters The spread of the ‘Delta Plus’ subvariant is a reminder of where visions of our COVID future diverge
BYDavid Meyer
November 18, 2021
Newsletters Medical boards are still struggling to discipline doctors who spread COVID-19 myths
BYYasmin Tayag
November 11, 2021
Newsletters Medicare negotiating drug prices could be the game changer Americans need
BYYasmin Tayag
November 4, 2021
Newsletters COVID vaccines could be the key to solving the global youth mental health emergency
BYYasmin Tayag
October 28, 2021
Newsletters Why the FDA’s ruling on mixing and matching vaccines will help more people get boosters
BYYasmin Tayag
October 21, 2021
Newsletters The stalemate over patents is fueling vaccine inequity—and the pandemic
BYYasmin Tayag
October 14, 2021
Newsletters Why Merck’s antiviral pill is not a silver bullet for COVID
BYYasmin Tayag
October 7, 2021
Newsletters Will vaccine mandates worsen the ongoing health care shortage?
BYYasmin Tayag
September 30, 2021
Newsletters The science behind a fond farewell
BYSy Mukherjee
September 23, 2021

Most Popular